Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
19 hedge funds and large institutions have $2.2M invested in Trillium Therapeutics Inc. in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 7 closing their positions.
21% less funds holding
Funds holding: 24 → 19 (-5)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
52% less capital invested
Capital invested by funds: $4.62M → $2.2M (-$2.42M)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$142K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.2K |
| 3 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
+$17.3K |
| 4 |
VF
Virtu Financial
New York
|
+$10.1K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$77 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$112K |
| 2 |
AG
Artal Group
Luxembourg
|
-$99K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$73K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$65K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of America
Charlotte,
North Carolina
| – | +$77 | +150 | +150% |
|
TRIL Hedge Fund Activity: Q2 2019 in Review
19 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q2 2019, worth a combined $2.2M — down 52% from $4.62M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TRIL and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Morgan Stanley, adding an estimated $142K. The largest seller was Platinum Investment Management, exiting entirely with an estimated $112K sold.
- 19 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q2 2019, down from 24 in Q1 2019.
- Funds reported $2.2M of Trillium Therapeutics Inc. stock for Q2 2019, down 52% quarter-over-quarter.
- 2 funds opened new Trillium Therapeutics Inc. positions in Q2 2019 and 7 closed out, a net change of -5 holders.
- The largest Trillium Therapeutics Inc. buyer in Q2 2019 was Morgan Stanley, an estimated $142K added.
- The largest Trillium Therapeutics Inc. seller in Q2 2019 was Platinum Investment Management, an estimated $112K sold.
Based on aggregated 13F filings for Q2 2019.